{
    "organizations": [],
    "uuid": "fbc5e5f974630c0b5e9eba2cf252abc79bdce51f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-gensight-biologics-obtains-authori/brief-gensight-biologics-obtains-authorization-of-mhra-to-start-clinical-study-of-phase-i-ii-pioneer-of-gene-therapy-gs030-idUSFWN1P412P",
    "ord_in_thread": 0,
    "title": "BRIEF-Gensight Biologics Obtains Authorization Of Mhra To Start Clinical Study Of Phase I/II Pioneer Of Gene Therapy GS030‍​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 10 (Reuters) - GENSIGHT BIOLOGICS SA:\n* GENSIGHT OBTAINS AUTHORIZATION OF MHRA TO START CLINICAL STUDY OF PHASE I/II PIONEER OF GENE THERAPY GS030‍​\n* EXPECTS TO TREAT FIRST PATIENT IN UK IN Q1 2018‍​‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-01-10T14:43:00.000+02:00",
    "crawled": "2018-01-11T12:26:52.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "gensight",
        "biologics",
        "sa",
        "gensight",
        "obtains",
        "authorization",
        "mhra",
        "start",
        "clinical",
        "study",
        "phase",
        "pioneer",
        "gene",
        "therapy",
        "expects",
        "treat",
        "first",
        "patient",
        "uk",
        "q1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}